Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Ulcerative Colitis HELP
Based on 8,733 articles since 2006

These are the 8733 published articles about Colitis, Ulcerative that originated from Worldwide during 2006-2015.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. 2015

Bressler, Brian / Marshall, John K / Bernstein, Charles N / Bitton, Alain / Jones, Jennifer / Leontiadis, Grigorios I / Panaccione, Remo / Steinhart, A Hillary / Tse, Francis / Feagan, Brian / Anonymous6260807. ·Division of Gastroenterology, Department of Medicine, St Paul's Hospital, Vancouver, British Columbia. Electronic address: brian_bressler@hotmail.com. · Department of Medicine, McMaster University, Hamilton, Ontario. · IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba. · Department of Medicine, McGill University Health Centre, Montreal, Quebec. · Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan. · Department of Medicine, University of Calgary, Calgary, Alberta. · Department of Medicine, University of Toronto, Toronto, Ontario. · Robarts Research Institute, Western University, London, Ontario, Canada. · ·Gastroenterology · Pubmed #25747596.

ABSTRACT: BACKGROUND & AIMS: The medical management of ulcerative colitis (UC) has improved through the development of new therapies and novel approaches that optimize existing drugs. Previous Canadian consensus guidelines addressed the management of severe UC in the hospitalized patient. We now present consensus guidelines for the treatment of ambulatory patients with mild to severe active UC. METHODS: A systematic literature search identified studies on the management of UC. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a working group of specialists. RESULTS: The participants concluded that the goal of therapy is complete remission, defined as both symptomatic and endoscopic remission without corticosteroid therapy. The consensus includes 34 statements focused on 5 main drug classes: 5-aminosalicylate (5-ASA), corticosteroids, immunosuppressants, anti-tumor necrosis factor (TNF) therapies, and other therapies. Oral and rectal 5-ASA are recommended first-line therapy for mild to moderate UC, with corticosteroid therapy for those who fail to achieve remission. Patients with moderate to severe UC should undergo a course of oral corticosteroid therapy, with transition to 5-ASA, thiopurine, anti-TNF (with or without thiopurine or methotrexate), or vedolizumab maintenance therapy in those who successfully achieve symptomatic remission. For patients with corticosteroid-resistant/dependent UC, anti-TNF or vedolizumab therapy is recommended. Timely assessments of response and remission are critical to ensuring optimal outcomes. CONCLUSIONS: Optimal management of UC requires careful patient assessment, evidence-based use of existing therapies, and thorough assessment to define treatment success.

2 Guideline Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease. 2015

Aalykke, Claus / Jensen, Michael Dam / Fallingborg, Jan / Jess, Tine / Langholz, Ebbe / Meisner, Søren / Andersen, Nynne Nyboe / Riis, Lene Buhl / Thomsen, Ole Østergaard / Tøttrup, Anders. ·Department of Medicine, OUH, Svendborg Sygehus, 5700 Svendborg, Denmark. claus.aalykke@rsyd.dk. · ·Dan Med J · Pubmed #25557336.

ABSTRACT: The risk of colorectal cancer (CRC) and dysplasia in patients with inflammatory bowel disease (IBD) has been highly debated as risk estimates from different studies vary greatly. The present national Danish guideline on colonoscopy surveillance for dysplasia and colorectal cancer in patients with IBD is based on a thorough review of existing literature with particular focus on recent studies from Denmark revealing a lower risk of CRC than previously assumed. The overall risk of CRC in the Danish IBD population does not appear to be different from that of the background population; however, in some subgroups of patients the risk is increased. These subgroups of patients, who should be offered colonoscopy surveillance, include patients with ulcerative colitis having extensive disease and a long disease duration (10-13 years); early age at onset (less than 19 years of age) of ulcerative colitis; and patients with ulcerative colitis as well as Crohn's disease with a concomitant diagnosis of primary sclerosing cholangitis. A colonoscopy surveillance program is recommended in these subgroups with intervals ranging from every 3-6 months to every 5 years, using chromoendoscopy with targeted biopsies of the lesion and adjacent mucosa, instead of conventional colonoscopy with random biopsies. Preferably, the colonoscopy should be performed during clinical remission. If a lesion is detected the endoscopical resectability together with the pathology of the lesion and the adjacent mucosa determine how the lesion should be treated.

3 Guideline Practice parameters for the surgical treatment of ulcerative colitis. 2014

Ross, Howard / Steele, Scott R / Varma, Mika / Dykes, Sharon / Cima, Robert / Buie, W Donald / Rafferty, Janice / Anonymous670769. ·Prepared by the Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. · ·Dis Colon Rectum · Pubmed #24316941.

ABSTRACT: -- No abstract --

4 Guideline ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. 2014

Levine, Arie / Koletzko, Sibylle / Turner, Dan / Escher, Johanna C / Cucchiara, Salvatore / de Ridder, Lissy / Kolho, Kaija-Leena / Veres, Gabor / Russell, Richard K / Paerregaard, Anders / Buderus, Stephan / Greer, Mary-Louise C / Dias, Jorge A / Veereman-Wauters, Gigi / Lionetti, Paolo / Sladek, Malgorzata / Martin de Carpi, Javier / Staiano, Annamaria / Ruemmele, Frank M / Wilson, David C / Anonymous2020782. ·*Pediatric Gastroenterology and Nutrition Unit, Wolfson Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel †Dr von Hauner Children's Hospital, Ludwig Maximilians University, Munich, Germany ‡Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel §Pediatric Gastroenterology, Department of Pediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands ||Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Italy ¶Children's Hospital, University of Helsinki, Helsinki, Finland #Semmelweis University, Budapest, Hungary **Department of Paediatric Gastroenterology and Nutrition, Yorkhill Children's Hospital, Glasgow, UK ††Department of Paediatrics, Hvidovre University Hospital, Copenhagen, Denmark ‡‡St.-Marien-Hospital, Department of Pediatrics, Bonn, Germany §§Department of Diagnostic Imaging, The Hospital for Sick Children ||||Department of Medical Imaging, University of Toronto, Toronto Canada ¶¶Hospital S. João, Porto, Portugal ##Pediatric Gastroenterology and Nutrition, UZ Brussels, Brussels, Belgium ***Departement Neurofarba, University of Florence, Meyer Children Hospital, Florence, Italy †††Department of Pediatrics, Gastroenterology and Nutrition, Jagiellonian University Medical College, Cracow, Poland ‡‡‡Department of Pediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain §§§Department of Translational Medical Sciences, Section of Pediatrics, University of Naples "Federico II," Naples, Italy ||||||Université Sorbonne Paris Cité, Université Paris Descartes, INSERM U989, AP-HP, Hôpital Necker Enfants Malades, Service de Gastroentérologie Pédiatrique, Paris, France ¶¶¶Child Life and Health, University of Edinburgh, Edinburgh, UK. · ·J Pediatr Gastroenterol Nutr · Pubmed #24231644.

ABSTRACT: BACKGROUND: The diagnosis of pediatric-onset inflammatory bowel disease (PIBD) can be challenging in choosing the most informative diagnostic tests and correctly classifying PIBD into its different subtypes. Recent advances in our understanding of the natural history and phenotype of PIBD, increasing availability of serological and fecal biomarkers, and the emergence of novel endoscopic and imaging technologies taken together have made the previous Porto criteria for the diagnosis of PIBD obsolete. METHODS: We aimed to revise the original Porto criteria using an evidence-based approach and consensus process to yield specific practice recommendations for the diagnosis of PIBD. These revised criteria are based on the Paris classification of PIBD and the original Porto criteria while incorporating novel data, such as for serum and fecal biomarkers. A consensus of at least 80% of participants was achieved for all recommendations and the summary algorithm. RESULTS: The revised criteria depart from existing criteria by defining 2 categories of ulcerative colitis (UC, typical and atypical); atypical phenotypes of UC should be treated as UC. A novel approach based on multiple criteria for diagnosing IBD-unclassified (IBD-U) is proposed. Specifically, these revised criteria recommend upper gastrointestinal endoscopy and ileocolonscopy for all suspected patients with PIBD, with small bowel imaging (unless typical UC after endoscopy and histology) by magnetic resonance enterography or wireless capsule endoscopy. CONCLUSIONS: These revised Porto criteria for the diagnosis of PIBD have been developed to meet present challenges and developments in PIBD and provide up-to-date guidelines for the definition and diagnosis of the IBD spectrum.

5 Guideline [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. 2013

Gomollón, Fernando / García-López, Santiago / Sicilia, Beatriz / Gisbert, Javier P / Hinojosa, Joaquín / Anonymous640763. · ·Gastroenterol Hepatol · Pubmed #24215088.

ABSTRACT: -- No abstract --

6 Guideline Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED). 2013

Peyrin-Biroulet, Laurent / Bonnaud, Guillaume / Bourreille, Arnaud / Chevaux, Jean-Baptiste / Faure, Patrick / Filippi, Jérôme / Laharie, David / Vuitton, Lucine / Bulois, Philippe / Gonzalez, Florent / Trang, Caroline / Koch, Stéphane / Bernardini, David / Cellier, Christophe / Anonymous2240762. ·Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy-Brabois, Université Henri Poincaré 1, 54511 Vandoeuvre-lès-Nancy. · ·Endoscopy · Pubmed #24165822.

ABSTRACT: -- No abstract --

7 Guideline European consensus on the histopathology of inflammatory bowel disease. 2013

Magro, F / Langner, C / Driessen, A / Ensari, A / Geboes, K / Mantzaris, G J / Villanacci, V / Becheanu, G / Borralho Nunes, P / Cathomas, G / Fries, W / Jouret-Mourin, A / Mescoli, C / de Petris, G / Rubio, C A / Shepherd, N A / Vieth, M / Eliakim, R / Anonymous4920758 / Anonymous4930758. ·Department of Pharmacology & Therapeutics, Institute for Molecular and Cell Biology, Faculty of Medicine University of Porto, Department of Gastroenterology, Hospital de Sao Joao, Porto, Portugal. Electronic address: fm@med.up.pt. · ·J Crohns Colitis · Pubmed #23870728.

ABSTRACT: The histologic examination of endoscopic biopsies or resection specimens remains a key step in the work-up of affected inflammatory bowel disease (IBD) patients and can be used for diagnosis and differential diagnosis, particularly in the differentiation of UC from CD and other non-IBD related colitides. The introduction of new treatment strategies in inflammatory bowel disease (IBD) interfering with the patients' immune system may result in mucosal healing, making the pathologists aware of the impact of treatment upon diagnostic features. The European Crohn's and Colitis Organisation (ECCO) and the European Society of Pathology (ESP) jointly elaborated a consensus to establish standards for histopathology diagnosis in IBD. The consensus endeavors to address: (i) procedures required for a proper diagnosis, (ii) features which can be used for the analysis of endoscopic biopsies, (iii) features which can be used for the analysis of surgical samples, (iv) criteria for diagnosis and differential diagnosis, and (v) special situations including those inherent to therapy. Questions that were addressed include: how many features should be present for a firm diagnosis? What is the role of histology in patient management, including search for dysplasia? Which features if any, can be used for assessment of disease activity? The statements and general recommendations of this consensus are based on the highest level of evidence available, but significant gaps remain in certain areas.

8 Guideline [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. 2013

Cabriada, José Luis / Vera, Isabel / Domènech, Eugeni / Barreiro-de Acosta, Manuel / Esteve, María / Gisbert, Javier P / Panés, Julia / Gomollón, Fernando / Anonymous2390743. ·Servicio de Aparato Digestivo, Hospital Galdakao-Usansolo, Galdakao, Vizcaya, España. jcabriada@gmail.com · ·Gastroenterol Hepatol · Pubmed #23433780.

ABSTRACT: -- No abstract --

9 Guideline Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. 2013

Gomollón, Fernando / García-López, Santiago / Sicilia, Beatriz / Gisbert, Javier P / Hinojosa, Joaquín / Anonymous2840741. ·Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Zaragoza, Spain. fgomollon@gmail.com · ·Gastroenterol Hepatol · Pubmed #23332546.

ABSTRACT: BACKGROUND AND AIM: Evidence-based clinical guidelines on Ulcerative colitis (UC) have been developed through a consensus, while GRADE methodology is the current standard for guideline development. This is the first one based on GRADE methodology on UC. METHODS: Following GRADE methodology, the Spanish Group of Ulcerative Colitis and Crohn's disease (GETECCU) have developed a guideline on UC treatment. After selection of relevant clinical scenarios, 32 clinical questions were chosen and recommendations were established. RESULTS: In 2 questions no recommendation was possible. Twenty-two actions were recommended for, 14 strongly and 8 weakly. However, in 8 questions a recommendation against doing something was obtained, weak in 5 and strong in 3. The majority of recommendations were based on moderate quality evidence, and only 5 on high-quality evidence. CONCLUSIONS: With GRADE methodology we find a clear recommendation on possible actions in most clinical decisions in UC treatment, but much more clinical high-quality research is needed.

10 Guideline Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. 2013

Van Assche, Gert / Dignass, Axel / Bokemeyer, Bernd / Danese, Silvio / Gionchetti, Paolo / Moser, Gabriele / Beaugerie, Laurent / Gomollón, Fernando / Häuser, Winfried / Herrlinger, Klaus / Oldenburg, Bas / Panes, Julian / Portela, Francisco / Rogler, Gerhard / Stein, Jürgen / Tilg, Herbert / Travis, Simon / Lindsay, James O / Anonymous210739. ·Division of Gastroenterology, Department of Medicine, Mt. Sinai Hospital and University Health Network,University of Toronto and University of Leuven, 600 University Avenue, Toronto, ON, Canada M5G 1X5. gvanassche@mtsinai.on.ca · ·J Crohns Colitis · Pubmed #23040453.

ABSTRACT: -- No abstract --

11 Guideline Indian Society of Gastroenterology consensus on ulcerative colitis. 2012

Ramakrishna, Balakrishnan S / Makharia, Govind K / Abraham, Philip / Ghoshal, Uday C / Jayanthi, Venkataraman / Agarwal, Brij Kishore / Ahuja, Vineet / Bhasin, Deepak K / Bhatia, Shobna J / Choudhuri, Gourdas / Dadhich, Sunil / Desai, Devendra C / Dhali, Gopal Krishna / Goswami, Bhaba Dev / Issar, Sanjeev K / Jain, Ajay K / Kochhar, Rakesh / Kumar, Ajay / Loganathan, Goundappa / Misra, Sri Prakash / Pai, C Ganesh / Pal, Sujoy / Pulimood, Anna / Puri, Amarender S / Ramesh, Ganesh N / Ray, Gautam / Singh, Shivaram P / Sood, Ajit / Tandan, Manu / Anonymous6070732. ·Department of Gastrointestinal Sciences, Christian Medical College, Vellore 632 004, India. rama@cmcvellore.ac.in · ·Indian J Gastroenterol · Pubmed #23096266.

ABSTRACT: In 2010, the Indian Society of Gastroenterology's Task Force on Inflammatory Bowel Diseases undertook an exercise to produce consensus statements on ulcerative colitis. This consensus, produced through a modified Delphi process, reflects our current understanding of the definition, diagnostic work up, treatment and complications of ulcerative colitis. The consensus statements are intended to serve as a reference point for teaching, clinical practice, and research in India.

12 Guideline Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. 2012

Turner, Dan / Levine, Arie / Escher, Johanna C / Griffiths, Anne M / Russell, Richard K / Dignass, Axel / Dias, Jorge Amil / Bronsky, Jiri / Braegger, Christian P / Cucchiara, Salvatore / de Ridder, Lissy / Fagerberg, Ulrika L / Hussey, Séamus / Hugot, Jean-Pierre / Kolacek, Sanja / Kolho, Kaija Leena / Lionetti, Paolo / Paerregaard, Anders / Potapov, Alexander / Rintala, Risto / Serban, Daniela E / Staiano, Annamaria / Sweeny, Brian / Veerman, Gigi / Veres, Gabor / Wilson, David C / Ruemmele, Frank M / Anonymous3370725 / Anonymous3380725. ·Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel. turnerjd2001@gmail.com · ·J Pediatr Gastroenterol Nutr · Pubmed #22773060.

ABSTRACT: BACKGROUND AND AIMS: Pediatric ulcerative colitis (UC) shares many features with adult-onset disease but there are some unique considerations; therefore, therapeutic approaches have to be adapted to these particular needs. We aimed to formulate guidelines for managing UC in children based on a systematic review (SR) of the literature and a robust consensus process. The present article is a product of a joint effort of the European Crohn's and Colitis Organization (ECCO) and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). METHODS: A group of 27 experts in pediatric IBD participated in an iterative consensus process including 2 face-to-face meetings, following an open call to ESPGHAN and ECCO members. A list of 23 predefined questions were addressed by working subgroups based on a SR of the literature. RESULTS: A total of 40 formal recommendations and 68 practice points were endorsed with a consensus rate of at least 89% regarding initial evaluation, how to monitor disease activity, the role of endoscopic evaluation, medical and surgical therapy, timing and choice of each medication, the role of combined therapy, and when to stop medications. A management flowchart, based on the Pediatric Ulcerative Colitis Activity Index (PUCAI), is presented. CONCLUSIONS: These guidelines provide clinically useful points to guide the management of UC in children. Taken together, the recommendations offer a standardized protocol that allows effective, timely management and monitoring of the disease course, while acknowledging that each patient is unique.

13 Guideline [Guidelines for the management of ulcerative colitis]. 2012

Choi, Chang Hwan / Kim, Young-Ho / Kim, You Sun / Ye, Byong Duk / Lee, Kang Moon / Lee, Bo In / Jung, Sung-Ae / Kim, Won Ho / Lee, Heeyoung / Anonymous90712. ·Department of Internal Medicine, Chung-Ang University College of Medicine, Korea. · ·Korean J Gastroenterol · Pubmed #22387836.

ABSTRACT: Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The quality of life can decreases significantly during exacerbations of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies are currently used for the management of UC. However, many challenging issues exist and sometimes these lead to differences in practice between clinicians. Therefore, Inflammatory Bowel Diseases (IBD) Study Group of Korean Association for the Study of Intestinal Diseases (KASID) set out the Korean guidelines for the management of UC. These guidelines are made by the adaptation using several foreign guidelines and encompass treatment of active colitis, maintenance of remission and indication for surgery in UC. The specific recommendations are presented with the quality of evidence. These are the first Korean treatment guidelines for UC and will be revised with new evidences on treatment of UC.

14 Guideline Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. 2012

Bitton, Alain / Buie, Donald / Enns, Robert / Feagan, Brian G / Jones, Jennifer L / Marshall, John K / Whittaker, Scott / Griffiths, Anne M / Panaccione, Remo / Anonymous4950709. ·McGill University Health Centre, Montreal, Quebec, Canada. alain.bitton@muhc.mcgill.ca · ·Am J Gastroenterol · Pubmed #22108451.

ABSTRACT: OBJECTIVES: The objective of this study was to provide updated explicit and relevant consensus statements for clinicians to refer to when managing hospitalized adult patients with acute severe ulcerative colitis (UC). METHODS: The Canadian Association of Gastroenterology consensus group of 23 voting participants developed a series of recommendation statements that addressed pertinent clinical questions. An iterative voting and feedback process was used to do this in conjunction with systematic literature reviews. These statements were brought to a formal consensus meeting held in Toronto, Ontario (March 2010), when each statement was discussed, reformulated, voted upon, and subsequently revised until group consensus (at least 80% agreement) was obtained. The modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria were used to rate the strength of recommendations and the quality of evidence. RESULTS: As a result of the iterative process, consensus was reached on 21 statements addressing four themes (General considerations and nutritional issues, Steroid use and predictors of steroid failure, Cyclosporine and infliximab, and Surgical issues). CONCLUSIONS: Key recommendations for the treatment of hospitalized patients with severe UC include early escalation to second-line medical therapy with either infliximab or cyclosporine in individuals in whom parenteral steroids have failed after 72 h. These agents should be used in experienced centers where appropriate support is available. Sequential therapy with cyclosporine and infliximab is not recommended. Surgery is an option when first-line steroid therapy fails, and is indicated when second-line medical therapy fails and/or when complications arise during the hospitalization.

15 Guideline [Surveillance of patients with inflammatory bowel diseases]. 2011

Moshkowitz, Menachem / Kariv, Revital / Half, Betsei / Vilkin, Alex / Levi, Zohar / Niv, Yaron / Dotan, Iris / Anonymous3270703. ·The Section of Gastrointestinal Oncology, the Israeli Gastroenterology Association. · ·Harefuah · Pubmed #22164923.

ABSTRACT: This position paper of the Section of Gastrointestinal Oncology of the Israeli Gastroenterological Association recommends specific guidelines for colorectal cancer surveillance in patients with inflammatory bowel disease. Colorectal cancer (CRC) is a severe complication of inflammatory bowel disease (IBD), generally developing into a longstanding disease. The Lifetime prevalence of CRC in ulcerative colitis (UC) patients is estimated to be 2% after 10 years, 8% after 20 years, and even 18% after 30 years of extensive disease. Screening colonoscopy should be initiated 8-10 years after onset of symptoms in extensive UC patients (pancolitis), and after 15 years in patients with left-sided colitis (UC or Crohn's). Surveillance should continue periodically at an interval of every 1 to 2 years. Surveillance colonoscopies should be performed in combination with an extensive biopsy protocol. High-grade dysplasia (HGD) in flat mucosa or a dysplasia associated Lesion or mass (DALM) is considered an indication for colectomy when the pathological findings are confirmed by a second experienced pathologist. Further research is directed toward improving detection of dysplasia during colonoscopy through the use of novel endoscopic imaging techniques which are hoped to impact the approach to cancer prevention in patients with IBD.

16 Guideline [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. 2011

Dignass, A / Preiss, J C / Aust, D E / Autschbach, F / Ballauff, A / Barretton, G / Bokemeyer, B / Fichtner-Feigl, S / Hagel, S / Herrlinger, K R / Jantschek, G / Kroesen, A / Kruis, W / Kucharzik, T / Langhorst, J / Reinshagen, M / Rogler, G / Schleiermacher, D / Schmidt, C / Schreiber, S / Schulze, H / Stange, E / Zeitz, M / Hoffmann, J C / Stallmach, A. ·Medizinische Klinik I, Gastroent., Hepatologie, Onkologie und Infektiologie, Agaplesion Markus Krankenhaus, Frankfurt/Main. axel.dignass@fdk.info · ·Z Gastroenterol · Pubmed #21866493.

ABSTRACT: -- No abstract --

17 Guideline Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. 2011

Turner, Dan / Travis, Simon P L / Griffiths, Anne M / Ruemmele, Frank M / Levine, Arie / Benchimol, Eric I / Dubinsky, Marla / Alex, George / Baldassano, Robert N / Langer, Jacob C / Shamberger, Robert / Hyams, Jeffrey S / Cucchiara, Salvatore / Bousvaros, Athos / Escher, Johanna C / Markowitz, James / Wilson, David C / van Assche, Gert / Russell, Richard K / Anonymous1480685 / Anonymous1490685. ·Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. turnerd@szmc.org.il · ·Am J Gastroenterol · Pubmed #21224839.

ABSTRACT: OBJECTIVES: Acute severe ulcerative colitis (ASC) is a potentially life-threatening disease. We aimed to formulate guidelines for managing ASC in children based on systematic review of the literature and robust consensus process. This manuscript is a product of a joint effort of the ECCO (European Crohn's and Colitis Organization), the Pediatric Porto Inflammatory Bowel Disease (IBD) Working group of ESPGHAN (European Society of Pediatric Gastroenterology, Hepatology, and Nutrition) and ESPGHAN. METHODS: A group of 19 experts in pediatric IBD participated in an iterative consensus process including two face-to-face meetings. A total of 17 predefined questions were addressed by working subgroups based on a systematic review of the literature. RESULTS: The recommendations and practice points were eventually endorsed with a consensus rate of at least 95% regarding: definitions, initial evaluation, standard therapy, timing of second-line therapy, the role of endoscopic evaluation and heparin prophylaxis, how to administer second-line medical therapy, how to assess response, surgical considerations, and discharge recommendations. A management flowchart is presented based on daily scoring of the Pediatric Ulcerative Colitis Activity Index (PUCAI), along with 28 formal recommendations and 34 practice points. CONCLUSIONS: These guidelines provide clinically useful points to guide the management of ASC in children. Taken together, the recommendations offer a standardized protocol that allows effective monitoring of disease progress and timely treatment escalation when needed.

18 Guideline The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. 2011

Orlando, Ambrogio / Armuzzi, Alessandro / Papi, Claudio / Annese, Vito / Ardizzone, Sandro / Biancone, Livia / Bortoli, Aurora / Castiglione, Fabiana / D'Incà, Renata / Gionchetti, Paolo / Kohn, Anna / Poggioli, Gilberto / Rizzello, Fernando / Vecchi, Maurizio / Cottone, Mario / Anonymous760678 / Anonymous770678. ·Department of Medicine, Pneumology and Nutrition Clinic, "V. Cervello" Hospital, Ospedali Riuniti "Villa Sofia-Cervello" University of Palermo, Italy. ambrogiorlando@tiscali.it · ·Dig Liver Dis · Pubmed #20843756.

ABSTRACT: Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn's and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these reasons the Italian Society of Gastroenterology and the Italian Group for the study of Inflammatory Bowel Disease have decided to elaborate the Italian guidelines on the use of biologics in Inflammatory Bowel Disease. The following items have been chosen: definitions of active, inactive, steroid dependent and resistant disease; measures of activity; anti-tumor necrosis factor alpha therapy use in active steroid dependent and refractory luminal Crohn's Disease, in fistulising Crohn's Disease, in steroid dependent and resistant active Ulcerative Colitis; risk of cancer; risk of infections during anti-tumor necrosis factor alpha therapy; special situations. These guidelines are based on evidence from relevant medical literature and clinical experience of a national working group.

19 Guideline Consensus guidelines for the management of inflammatory bowel disease. 2010

Anonymous5670674. · ·Arq Gastroenterol · Pubmed #21140096.

ABSTRACT: This is the first Brazilian Consensus on inflammatory bowel disease, carried out by the Brazilian Study Group of Inflammatory Bowel Disease, and discusses the treatment of Crohn's disease and ulcerative colitis in acute and remission phases. The first part of the text, brings out a review on the main drugs used in the treatment of inflammatory bowel disease, as well as their mechanisms of action and cautions during their use. In the second part, the committee's opinions about the most recommended medical and surgical approaches for both diseases are presented on the basis of disease activity, location and behaviour status. The recommendations here presented were widely discussed in several scientific meetings with active participation of all members of the group and were highly based on scientific evidence covered by the literature.

20 Guideline Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. 2010

Kornbluth, Asher / Sachar, David B / Anonymous2830655. ·Samuel Bronfman Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA. asher.kornbluth@mssm.edu · ·Am J Gastroenterol · Pubmed #20068560.

ABSTRACT: Guidelines for clinical practice are aimed to indicate preferred approaches to medical problems as established by scientifically valid research. Double-blind placebo controlled studies are preferable, but compassionate-use reports and expert review articles are used in a thorough review of the literature conducted through Medline with the National Library of Medicine. When only data that will not withstand objective scrutiny are available, a recommendation is identified as a consensus of experts. Guidelines are applicable to all physicians who address the subject regardless of specialty training or interests and are aimed to indicate the preferable but not necessarily the only acceptable approach to a specific problem. Guidelines are intended to be flexible and must be distinguished from standards of care, which are inflexible and rarely violated. Given the wide range of specifics in any health-care problem, the physician must always choose the course best suited to the individual patient and the variables in existence at the moment of decision. Guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the board of trustees. Each has been intensely reviewed and revised by the Committee, other experts in the field, physicians who will use them, and specialists in the science of decision analysis. The recommendations of each guideline are therefore considered valid at the time of composition based on the data available. New developments in medical research and practice pertinent to each guideline will be reviewed at a time established and indicated at publication to assure continued validity. The recommendations made are based on the level of evidence found. Grade A recommendations imply that there is consistent level 1 evidence (randomized controlled trials), grade B indicates that the evidence would be level 2 or 3, which are cohort studies or case-control studies. Grade C recommendations are based on level 4 studies, meaning case series or poor-quality cohort studies, and grade D recommendations are based on level 5 evidence, meaning expert opinion.

21 Guideline [Diagnostic guideline of ulcerative colitis]. 2009

Choi, Chang Hwan / Jung, Sung Ae / Lee, Bo In / Lee, Kang Moon / Kim, Joo Sung / Han, Dong Soo / Anonymous2510644. ·Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. · ·Korean J Gastroenterol · Pubmed #19835217.

ABSTRACT: Ulcerative colitis is a chronic inflammatory disorder causing mucosal inflammation of the colorectum with crypt abnormality on biopsy. It affects the rectum and a variable extent of the colon in continuity. Ulcerative colitis is characterized by a relapsing and remitting course. It arises from an interaction between genetic and environmental factors, but the precise etiology is unknown. The incidence and prevalence in Korea are still low compared with those of Western countries, but have increased in recent years. There are many challenging issues on the diagnosis of ulcerative colitis, and sometimes these lead to differences in practice between clinicians. Therefore, IBD Study Group of KASID set out the Korean diagnostic guideline of ulcerative colitis. The diagnosis is based on clinical, endoscopic, radiologic, and histologic criteria. The symptoms are dependent upon the extent and severity of disease and most commonly include bloody diarrhea, rectal bleeding, and/or urgency. The systemic symptoms of malaise, tachycardia, fever, or weight loss are features of a severe attack. The laboratory findings may reveal leucocytosis, thrombocytosis, iron deficiency anemia, hypoalbuminemia, and elevated erythrocyte sedimentation rate and C-reactive protein indicating severe disease activity or chronicity. For the elimination of infectious causes, microbial investigation with stool specimens should be performed for common enteric pathogens including assays for Clostridium difficile toxin, and sometimes for amoeba or other parasites. The most typical endoscopic features are continuous, confluent, and concentric colonic involvement proximal to the anal verge. Endoscopic severity may be best well reflected by the presence of mucosal friability, spontaneous bleeding, and deep ulcerations. Typical pathologic findings are composed of widespread crypt architectural distortion (cryptitis, crypt abscess, and crypt atrophy), heavy, diffuse lamina propria cell infiltration, and basal plasmacytosis.

22 Guideline Clinical guidelines for the management of pouchitis. 2009

Pardi, Darrell S / D'Haens, Geert / Shen, Bo / Campbell, Simon / Gionchetti, Paolo. ·Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA. pardi.darrell@mayo.edu · ·Inflamm Bowel Dis · Pubmed #19685489.

ABSTRACT: When surgery is necessary in patients with ulcerative colitis, total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the procedure of choice. Several inflammatory and noninflammatory complications can occur after IPAA. Pouchitis is the most common, occurring in approximately 50% of patients. Whereas "acute" pouchitis can be treated rapidly and successfully in the majority of patients, "refractory" and "chronic pouchitis" remain therapeutic challenges to patients and physicians. This article reviews the literature and offers consensus guidelines on issues related to the epidemiology, diagnosis, pathogenesis, risk factors, and treatment of pouchitis.

23 Guideline Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. 2009

McLaughlin, Simon D / Clark, Susan K / Thomas-Gibson, Siwan / Tekkis, Paris P / Ciclitira, Paul J / Nicholls, R John. ·Department of Biosurgery and Surgical Technology, Imperial College, London, UK. simon.mclaughlin@nhs.net · ·Inflamm Bowel Dis · Pubmed #19180580.

ABSTRACT: Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis is the surgical procedure of choice for patients with ulcerative colitis (UC). It is also performed in selected patients with familial adenomatous polyposis (FAP). A significant proportion of patients will develop pouch dysfunction. Flexible pouchoscopy is the most important initial investigation in patients with dysfunction. It is also important in UC and FAP surveillance. The aim is to provide gastroenterologists with a clear understanding of the technique, indications, and diagnostic pitfalls when investigating RPC patients with flexible pouchoscopy. Flexible pouchoscopy for the investigation of RPC patients with pouch dysfunction has a high diagnostic yield, with most causes of pouch dysfunction identifiable during this procedure. The risk of developing dysplasia following RPC is low. Surveillance pouchoscopy is only recommended in those with FAP, those with a previous history of dysplasia or carcinoma, primary sclerosing cholangitis, those with a retained rectal cuff, and those with Type C histological changes. Flexible pouchoscopy is a useful first-line investigation in patients with pouch dysfunction. It can be performed without sedation and has a high diagnostic yield; it is also important as part of surveillance in FAP and selected UC patients.

24 Guideline Refractory inflammatory bowel disease in children. 2008

Oliva-Hemker, M / Escher, J C / Moore, D / Dubinksy, M / Hildebrand, H / Koda, Y K L / Murch, S / Sandhu, B / Seo, J K / Tanzi, M N / Warner, B / Anonymous5740613. ·Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2631, USA. moliva@jhmi.edu · ·J Pediatr Gastroenterol Nutr · Pubmed #18664886.

ABSTRACT: -- No abstract --

25 Guideline Consensus on the management of inflammatory bowel disease in China in 2007. 2008

Anonymous5460602 / Anonymous5470602 / Ouyang, Qin / Hu, Pin Jin / Qian, Jia Ming / Zheng, Jia Ju / Hu, Ren Wei. ·Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China. qin.ouyang@163.com · ·J Dig Dis · Pubmed #18251795.

ABSTRACT: -- No abstract --